Author(s):
Rose, Angela M.C. ; Nicolay, Nathalie ; Sandonis Martín, Virginia ; Mazagatos, Clara ; Petrović, Goranka ; Baruch, Joaquin ; Denayer, Sarah ; Seyler, Lucie ; Domegan, Lisa ; Launay, Odile ; Machado, Ausenda ; Burgui, Cristina ; Vaikutyte, Roberta ; Niessen, F Annabel ; Loghin, Isabela I. ; Husa, Petr ; Aouali, Nassera ; Panagiotakopoulos, George ; Tolksdorf, Kristin ; Horváth, Judit Krisztina ; Howard, Jennifer ; Pozo, Francisco ; Gallardo, Virtudes ; Nonković, Diana ; Džiugytė, Aušra ; Bossuyt, Nathalie ; Demuyser, Thomas ; Duffy, Róisín ; Luong Nguyen, Liem binh ; Kislaya, Irina ; Martínez-Baz, Iván ; Gefenaite, Giedre ; Knol, Mirjam J. ; Popescu, Corneliu ; Součková, Lenka ; Simon, Marc ; Michelaki, Stella ; Reiche, Janine ; Ferenczi, Annamária ; Delgado-Sanz, Concepción ; Lovrić Makarić, Zvjezdana ; Cauchi, John Paul ; Barbezange, Cyril ; Van Nedervelde, Els ; O’Donnell, Joan ; Durier, Christine ; Guiomar, Raquel ; Castilla, Jesús ; Jonikaite, Indrė ; Bruijning-Verhagen, Patricia C.J.L. ; Lazar, Mihaela ; Demlová, Regina ; Wirtz, Gil ; Amerali, Marina ; Dürrwald, Ralf ; Kunstár, Mihály Pál ; Kissling, Esther ; Bacci, Sabrina ; Valenciano, Marta ; I-MOVE-COVID-19 hospital study team ; VEBIS hospital study team ; Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above)
Date: 2023
Persistent ID: http://hdl.handle.net/10400.18/8871
Origin: Repositório Científico do Instituto Nacional de Saúde
Subject(s): COVID-19; SARS-CoV-2; Vaccine Effectiveness; Hospital; Omicron; VEBIS- LOTE 1; Vacina; Efetividade; Cuidados de Saúde; Infecções Respiratórias; Europe
Description
Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.
